BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

AI Briefing

• – BriaCell Therapeutics Corp. announces partnership with NYU Langone Health's Perlmutter Cancer Center for Phase 3 breast cancer study.
• – NYU Langone Health's Perlmutter Cancer Center to serve as clinical trial site for BriaCell's pivotal study.
• – BriaCell aims to develop novel immunotherapies for cancer care with new clinical trial partnership.